These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2808208)

  • 21. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
    Mushtaq S; Vickers A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response of chemostat cultures of Pseudomonas aeruginosa to carbapenems and other beta-lactams.
    Wu PJ; Livermore DM
    J Antimicrob Chemother; 1990 Jun; 25(6):891-902. PubMed ID: 2115037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects on beta-lactam susceptibility of phenotypic induction and genotypic derepression of beta-lactamase synthesis.
    Shannon K; Phillips I
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():15-22. PubMed ID: 3102451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins.
    Raimondi A; Traverso A; Nikaido H
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1174-80. PubMed ID: 1656855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa.
    Livermore DM; Yang YJ
    J Infect Dis; 1987 Apr; 155(4):775-82. PubMed ID: 3102630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inducible type I beta-lactamases of gram-negative bacteria and resistance to beta-lactam antibiotics.
    Curtis NA; Eisenstadt RL; Rudd C; White AJ
    J Antimicrob Chemother; 1986 Jan; 17(1):51-61. PubMed ID: 3485092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
    Chanal C; Sirot D; Chanal M; Cluzel M; Sirot J; Cluzel R
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():133-41. PubMed ID: 2808205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy.
    Schito GC; Sanna A; Chezzi C; Ravizzola G; Leone F; Molinari G; Menozzi MG; Pirali F
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():57-72. PubMed ID: 2681128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The postantibiotic effect of meropenem and imipenem on selected bacteria.
    Nadler HL; Pitkin DH; Sheikh W
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():225-31. PubMed ID: 2509416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of chromosomal beta-lactamases by different concentrations of clavulanic acid in combination with ticarcillin.
    Stobberingh EE
    J Antimicrob Chemother; 1988 Jan; 21(1):9-16. PubMed ID: 3128523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical and laboratory significance of inducible beta-lactamases].
    Bedenić B; Zagar Z
    Lijec Vjesn; 1995; 117(9-10):249-53. PubMed ID: 8643019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Preclinical evaluation of meropenem, a new parenteral carbapenem].
    Edwards JR
    New Microbiol; 1995 Oct; 18 Suppl():19S-31S. PubMed ID: 8574929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chromosomal beta-lactamase expression and antibiotic resistance in Enterobacter cloacae.
    Yang YJ; Livermore DM; Williams RJ
    J Med Microbiol; 1988 Mar; 25(3):227-33. PubMed ID: 3258037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity.
    Kessler RE; Fung-Tomc J; Kolek B; Minassian B; Huczko E; Gradelski E; Bonner DP
    Antimicrob Agents Chemother; 1995 Feb; 39(2):380-5. PubMed ID: 7726502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of OmpD2 and chromosomal beta-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa.
    Satake S; Yoneyama H; Nakae T
    J Antimicrob Chemother; 1991 Aug; 28(2):199-207. PubMed ID: 1778851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-vitro activity of meropenem against clinical isolates obtained in Canada.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():47-55. PubMed ID: 2808216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ability of beta-lactam antibiotics to select mutants with derepressed beta-lactamase synthesis from Citrobacter freundii.
    Stapleton P; Shannon K; Phillips I
    J Antimicrob Chemother; 1995 Sep; 36(3):483-96. PubMed ID: 8830012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics.
    Sanders CC; Sanders WE
    J Infect Dis; 1986 Nov; 154(5):792-800. PubMed ID: 3490520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro antibacterial activity and mechanism of action of J-111,225, a novel 1beta-methylcarbapenem, against transferable IMP-1 metallo-beta-lactamase producers.
    Nagano R; Adachi Y; Hashizume T; Morishima H
    J Antimicrob Chemother; 2000 Mar; 45(3):271-6. PubMed ID: 10702544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.